EnzyMark AI Lab Standard: An ultra-early warning enzymatic test for prescreening more than 100 diseases, with a primary focus on oncological risks, that detects abnormalities up to 1,000 times earlier than conventional markers.
Alterations may already appear at the level of one million tumor cells, with 99.9% system robustness, up to 98.6% sensitivity, and 94–96% accuracy.
Built on 50 years of research heritage, 25 years of method development, and more than 10,000 validated samples, EnzyMark AI rests on one of the strongest scientific foundations in the field.
It delivers actionable therapeutic feedback within 3 seconds, directly from laboratory results, after the effects of anesthetics have subsided, integrates seamlessly with existing laboratory infrastructure, and is easily scalable for both clinical and research environments.
We have observed that laboratory leaders who are open to introducing modern, enzyme-based testing solutions tend to share very similar long-term objectives:
-
A differentiated service that does not become subject to price competition
-
Earlier positioning in the patient journey, ahead of classical diagnostic workflows
-
A high-value test without significant investment risk
-
Physician-friendly operation that does not challenge medical decision authority
-
Stable and predictable profitability, driven by value creation rather than volume alone
At the same time, daily laboratory operations typically face the following challenges:
-
Classical laboratory diagnostics have become commoditized, with continuously shrinking margins
-
Introducing new tests is often slow, expensive, and commercially risky
-
Demand for early detection is increasing, while few truly effective solutions are available
-
Many innovations are designed for theoretical or marketing purposes, not for real laboratory operations
-
Very few systems are both clinically and commercially validated
The EnzyMark AI Lab Standard provides a proven, practical response to these challenges:
-
The system does not diagnose; it delivers early warning signals and risk profiles, fully preserving physician decision-making authority
-
Its operation is based on experience from more than 34,000 prior cases, and 10,000+ validated patient records support the evaluation
-
In oncological prescreening, sensitivity may reach up to 98.6% at an extremely early stage —potentially up to a thousand times earlier than commonly used tumor markers—when real preventive and clinical decision-making options still exist
-
The system operates with 99.9% operational stability in laboratory environments
-
It delivers therapeutic feedback within 3 seconds, enabling real-time monitoring of therapy.
-
Observed laboratory-side returns typically range between 300–614%
-
EnzyMark AI Lab Standard is built on existing laboratory infrastructure and does not require radical operational changes
How can you start using EnzyMark AI Lab Standard?
- The introduction of EnzyMark AI Lab Standard can begin with a one-, two-, or three-month onboarding period, depending on how quickly the laboratory aims to reach an operational testing volume.
- The one- and two-month options primarily support familiarization with the system and process validation, while testing volumes are gradually built up.
- Laboratories choosing the three-month onboarding period may receive an option for their geographical area, providing a potential strategic advantage in the region—especially once testing volumes have stabilized.
Why is this beneficial for you and your laboratory?
-
Because your laboratory enters the patient journey earlier, when real clinical and preventive decision space still exists
-
Because EnzyMark AI Lab Standard enables a high-value diagnostic offering, free from price-driven competition
-
Because the system is physician-friendly, supporting rather than replacing medical decision-making
-
Because the introduction follows a lightweight onboarding model, allowing the laboratory to reach operational scale with low initial risk
